Deep dive: Bioprocess scale-up & biomanufacturing economics — the fastest-moving subsegments to watch

Biomanufacturing has long promised to replace petrochemical processes with biological ones, converting sugars, CO2, and waste feedstocks into chemicals, materials, and fuels through engineered microorganisms and enzymes. The promise remains enormous: biomanufacturing could address up to 60% of the physical inputs to the global economy, according to McKinsey estimates. Yet the field's central challenge persists. The vast majority of bioprocesses that work brilliantly at 10-liter bench scale fail technically or economically when scaled to 100,000-liter commercial fermenters. Understanding which subsegments are breaking through this barrier, and which remain trapped in the "valley of death" between pilot and production, is essential for procurement teams evaluating biological alternatives to conventional supply chains.

Why It Matters

The bioeconomy is projected to reach $4 trillion in global output by 2030, up from approximately $1.5 trillion in 2024. Europe is positioning itself at the center of this transition through the EU Bioeconomy Strategy, Horizon Europe funding of over EUR 10 billion for bio-based innovation, and the European Green Deal's emphasis on circular, bio-based value chains. The European Industrial Biotechnology Association estimates that bio-based chemicals could capture 25% of the European chemical market by 2035, up from roughly 10% today.

For procurement professionals, biomanufactured alternatives are transitioning from niche sustainability plays to strategic supply chain decisions. Price parity has been achieved or is within reach for several high-volume chemicals. 1,4-butanediol (BDO), succinic acid, and lactic acid produced via fermentation now compete directly with petrochemical equivalents on cost in European markets. Meanwhile, the EU Carbon Border Adjustment Mechanism and expanding emissions trading system are steadily increasing the cost of carbon-intensive chemical production, further tilting the economics toward biological routes.

The scale-up challenge is not merely technical. Capital requirements for commercial biomanufacturing facilities range from EUR 150 million to EUR 500 million, with construction timelines of three to five years. Feedstock logistics, utility infrastructure, and regulatory approvals add complexity that pure laboratory performance cannot predict. The subsegments that are successfully navigating these challenges share common characteristics: robust organisms that tolerate industrial conditions, feedstock flexibility, and unit economics that close at realistic rather than optimistic yields.

Key Concepts

Continuous Fermentation replaces traditional batch processing (fill, ferment, harvest, clean, repeat) with steady-state operation where fresh media enters and product-containing broth exits continuously. The approach increases volumetric productivity by 30 to 60% and reduces downtime, but requires organisms engineered for genetic stability over thousands of generations and sophisticated process control to maintain steady state. Continuous fermentation has reached commercial scale for ethanol and some organic acids but remains developmental for most specialty chemicals and proteins.

Precision Fermentation uses genetically engineered microorganisms as cellular factories to produce specific high-value molecules, from proteins and enzymes to flavors and pigments, rather than harvesting them from animals or plants. Unlike traditional fermentation that produces bulk chemicals, precision fermentation targets molecules where biological production offers structural complexity that chemical synthesis cannot match, or where it eliminates animal agriculture dependencies with significant emissions implications.

Cell-Free Biomanufacturing extracts the enzymatic machinery from cells and uses it in vitro, bypassing the metabolic overhead and toxicity constraints of living organisms. Cell-free systems achieve higher product titers for toxic or metabolically burdensome products, with volumetric productivities 2 to 10x greater than cell-based fermentation for certain molecule classes. Commercial viability depends on enzyme cost and stability, which have improved dramatically through directed evolution and immobilization technologies.

Techno-Economic Analysis (TEA) provides the quantitative framework for evaluating bioprocess viability at scale. Rigorous TEA models incorporate feedstock costs, capital expenditure, operating costs, yield projections at scale (not bench scale), and downstream processing requirements to determine minimum selling price. The gap between bench-scale TEA projections and actual commercial economics has historically been 2 to 5x, primarily because bench-scale yields rarely survive the transition to large fermenters.

The Fastest-Moving Subsegments

Precision Fermentation for Dairy Proteins

This subsegment has attracted the most capital and achieved the most commercial traction of any precision fermentation category. Perfect Day (now The Urgent Company) operates commercial-scale production of whey protein in the United States, with product sold through partnerships with major dairy brands. In Europe, Formo (Berlin) reached pilot-scale casein production in 2025 and secured EUR 60 million in Series B funding to build its first commercial facility targeting 2027 operations. New Culture (San Francisco) produces mozzarella-functional casein at increasing scale.

The economics are converging rapidly. The cost of precision-fermented whey protein dropped from approximately $100 per kilogram in 2020 to $10 to $15 per kilogram in 2025, approaching the $3 to $6 per kilogram range of conventional dairy whey. Industry projections suggest cost parity by 2028 to 2029 at commercial scale. The key technical breakthrough has been strain engineering to achieve titers exceeding 20 grams per liter, combined with simplified downstream processing that eliminates the expensive chromatographic purification steps initially required.

For European procurement teams, the regulatory pathway is also clearing. The European Food Safety Authority (EFSA) issued its first positive scientific opinion on a precision-fermented protein ingredient in 2025, with full Novel Food authorization expected by late 2026. This regulatory milestone will unlock the European market, which represents the largest dairy market globally at over EUR 180 billion annually.

Gas Fermentation for Carbon-Negative Chemicals

Gas fermentation, using engineered acetogens to convert industrial waste gases (CO, CO2, and H2) into ethanol, acetone, and isopropanol, represents one of the few biomanufacturing subsegments that is simultaneously scalable, economically competitive, and carbon-negative. LanzaTech has demonstrated this at commercial scale with its first plant in Shougang, China, converting steel mill off-gases into 46,000 tonnes of ethanol annually since 2018. A second commercial facility in India began operations in 2024, and European projects with ArcelorMittal (Ghent, Belgium) are advancing toward final investment decisions.

The economics work because gas fermentation uses waste gases as feedstock, eliminating the sugar feedstock costs that typically represent 40 to 60% of conventional fermentation operating expenses. Capital intensity is comparable to traditional chemical plants at $1,000 to $2,000 per tonne of annual capacity. The carbon math is compelling: each tonne of ethanol produced from waste gases avoids approximately 1.8 tonnes of CO2 emissions compared to petrochemical ethanol and 0.8 tonnes compared to corn ethanol.

The subsegment is accelerating because the product slate is expanding beyond ethanol. LanzaTech and partners have demonstrated production of acetone, isopropanol, and jet fuel precursors from waste gases, with Zara parent company Inditex incorporating gas-fermented ethanol-derived polyester into commercial garments. European chemical buyers are particularly interested given the EU Emissions Trading System carbon price (currently EUR 60 to 80 per tonne) and forthcoming CBAM implications for imported chemicals.

Enzymatic Recycling of PET Plastics

The enzymatic recycling of polyethylene terephthalate (PET) has moved from laboratory curiosity to commercial reality faster than almost any other bioprocess application. Carbios (Clermont-Ferrand, France) opened the world's first industrial enzymatic PET recycling plant in Longlaville, France, in 2025, with capacity to process 50,000 tonnes of PET waste annually. The company's engineered PET hydrolase achieves over 90% depolymerization of post-consumer PET waste in under 10 hours, producing virgin-quality monomers (terephthalic acid and ethylene glycol) that can be repolymerized into food-grade PET.

The economic case is strengthening as virgin PET prices rise and regulatory mandates expand. The EU Single-Use Plastics Directive requires 25% recycled content in PET bottles by 2025 and 30% by 2030. Enzymatic recycling produces monomers at estimated costs of EUR 1,200 to 1,500 per tonne, compared to EUR 900 to 1,100 for virgin PET monomers, but the premium is increasingly justified by recycled content mandates and brand sustainability commitments. Carbios has offtake agreements with L'Oreal, Nestle Waters, PepsiCo, and Suntory, providing revenue visibility that de-risks further capacity expansion.

Samsara Eco (Australia) and Protein Evolution (United States) are developing competing enzymatic recycling platforms targeting broader polymer types beyond PET, including polyamides and polyurethanes. The subsegment benefits from a clear regulatory tailwind, proven unit economics at scale, and blue-chip customer demand.

Persistent Challenges

The Yield Cliff at Scale

The most common failure mode in bioprocess scale-up remains the decline in product yield when transitioning from bench to pilot to commercial scale. Oxygen transfer limitations in large fermenters, shear stress from impeller mixing, and temperature gradients create conditions that small-scale vessels cannot replicate. A 2024 meta-analysis in Metabolic Engineering examined 280 bioprocesses and found that median yield at 10,000-liter scale was 62% of yield achieved at 1-liter scale. For aerobic processes producing hydrophobic products, the yield decline was more severe: median scale-up yield retention of only 45%. This persistent gap means that bench-scale TEA models systematically overestimate commercial viability, leading to inflated investor expectations and disappointing commercial outcomes.

Downstream Processing Cost Dominance

For many biomanufactured products, the cost of extracting and purifying the target molecule from fermentation broth exceeds the cost of fermentation itself. Downstream processing (DSP) typically accounts for 40 to 70% of total manufacturing cost for precision-fermented proteins and specialty chemicals. Traditional DSP methods (centrifugation, chromatography, crystallization) were designed for pharmaceutical applications where product values of $1,000 or more per kilogram justify expensive purification. For commodity and specialty chemicals selling at $2 to $20 per kilogram, DSP costs must decrease by 5 to 10x for viable economics. Membrane-based separation, aqueous two-phase extraction, and in situ product removal technologies are advancing but remain below the reliability thresholds required for continuous commercial operation.

Feedstock Volatility and Competition

Sugar-based fermentation processes remain exposed to agricultural commodity price volatility. European sugar prices fluctuated between EUR 350 and EUR 800 per tonne over the past three years, directly impacting the economics of fermentation processes where sugar typically represents 30 to 50% of variable costs. Second-generation feedstocks (lignocellulosic biomass, agricultural residues) reduce cost exposure but introduce pretreatment complexity and variability that most production organisms cannot tolerate. The competition for biomass feedstocks among bioenergy, biomaterials, and biochemicals applications is intensifying, with EU sustainability criteria under the Renewable Energy Directive III adding compliance costs and supply constraints.

What's Next

Modular and Distributed Biomanufacturing

The traditional model of centralized mega-facilities is being challenged by modular biomanufacturing concepts. Companies including Synonym Bio and Culture Biosciences offer standardized, containerized fermentation modules that can be deployed at or near feedstock sources, reducing logistics costs and enabling faster capacity deployment. A modular 50,000-liter facility can be operational in 12 to 18 months at a capital cost of EUR 10 to 30 million, compared to three to five years and EUR 150 million or more for conventional construction. European procurement teams should evaluate whether distributed production closer to feedstock and demand centers offers supply chain resilience advantages over centralized supply.

AI-Optimized Bioprocess Control

Machine learning applied to fermentation process control is delivering measurable improvements in consistency and yield. Zymergen (now part of Ginkgo Bioworks) and Culture Biosciences have demonstrated 10 to 20% yield improvements through AI-driven optimization of feed rates, dissolved oxygen, pH trajectories, and temperature profiles. The approach is particularly valuable at scale, where the interaction effects between process variables become too complex for human operators to optimize manually. Real-time spectroscopic monitoring combined with predictive models enables proactive intervention before yield-limiting conditions develop.

Carbon Credit Integration

Bioprocesses that convert waste streams or CO2 into valuable products are increasingly stacking carbon credit revenue on top of product sales. Under Article 6 of the Paris Agreement and voluntary carbon market frameworks, gas fermentation and enzymatic recycling processes can generate verified carbon credits. LanzaTech's CarbonSmart platform enables brand partners to claim and communicate the carbon benefit of products made from waste carbon. As carbon credit prices in compliance markets continue rising, this additional revenue stream improves the economics of bioprocesses that are marginally viable on product sales alone.

Key Players

Established Leaders

Novozymes (now Novonesis) dominates industrial enzyme supply, with over 50% global market share in enzymes for biofuel, food, and textile applications. Their enzyme engineering platform underpins many third-party bioprocess scale-up efforts.

DSM-Firmenich operates one of Europe's largest precision fermentation platforms, producing vitamins, flavors, and specialty ingredients at commercial scale across multiple facilities.

LanzaTech leads gas fermentation commercialization with two operating commercial plants and a growing pipeline of European and North American projects.

Emerging Startups

Carbios has demonstrated enzymatic PET recycling at industrial scale, with its first commercial plant operational in France.

Formo is advancing precision-fermented dairy proteins toward commercial scale in Europe, targeting the EUR 180 billion European dairy market.

Synonym Bio provides biomanufacturing capacity-as-a-service, enabling companies to access fermentation infrastructure without building their own facilities.

Key Investors and Funders

Novo Holdings has deployed over $1 billion into industrial biotechnology, with a thesis centered on replacing petrochemical supply chains with biological alternatives.

Sofinnova Partners is one of Europe's most active bioeconomy investors, with a dedicated Industrial Biotechnology fund.

European Innovation Council (EIC) provides blended finance (grants plus equity) for breakthrough bioprocess technologies through its Accelerator program, with over EUR 500 million deployed into bioeconomy startups since 2021.

Action Checklist

• Map current chemical and material procurement spend to identify categories where bio-based alternatives have reached cost parity or are within 20% premium
• Request detailed TEA documentation from biomanufacturing suppliers, including demonstrated (not projected) yields at commercial scale
• Evaluate supply security: assess whether suppliers operate at commercial scale or are still at pilot stage before committing to long-term contracts
• Factor in carbon pricing impacts on conventional supply: model how EU ETS prices of EUR 80 to 120 per tonne would shift total cost of ownership toward bio-based alternatives
• Engage with modular biomanufacturing providers to assess whether distributed production models offer resilience advantages for your supply chain
• Include sustainability and carbon intensity specifications in procurement RFPs to capture the full value proposition of biomanufactured inputs
• Monitor EFSA Novel Food authorizations for precision-fermented ingredients relevant to your product portfolio
• Establish pilot procurement agreements (1 to 2 year terms) with emerging biomanufacturing suppliers to build supply chain experience before scaling commitments

FAQ

Q: At what price point do biomanufactured chemicals become competitive with petrochemical equivalents? A: It varies by product category. Bulk chemicals (ethanol, organic acids) achieve parity when fermentation costs reach $500 to $800 per tonne, which gas fermentation and optimized sugar fermentation now approach. Specialty chemicals ($5 to $50 per kilogram) often reach parity when fermentation titers exceed 50 to 100 grams per liter. Precision-fermented proteins are competitive at $5 to $15 per kilogram for high-value applications. The carbon price effectively subsidizes bio-based routes: every EUR 10 per tonne increase in EU ETS carbon price reduces the breakeven threshold for biomanufactured alternatives.

Q: How reliable is supply from biomanufacturing companies that have recently scaled? A: Supply reliability improves significantly once producers have completed at least 12 months of continuous commercial operation. Expect 85 to 90% on-time delivery rates during the first year of commercial production, improving to 95% or above after process stabilization. Procurement teams should maintain dual-source strategies during the first two to three years and negotiate force majeure protections that account for biological production risks (contamination, strain instability) that do not apply to chemical manufacturing.

Q: What due diligence should procurement teams conduct before contracting with biomanufacturing suppliers? A: Key diligence areas include: demonstrated production at commercial scale (not just pilot results); financial runway sufficient to sustain operations for 18 to 24 months without additional fundraising; customer references from comparable procurement relationships; quality management certifications (ISO 9001, FSSC 22000 for food ingredients); and transparent TEA models validated against actual production data. Red flags include suppliers citing only bench-scale yields, projecting costs based on "future" strain improvements, or lacking independent quality audits.

Q: Which European regulations are most relevant to bio-based chemical procurement? A: The EU Bioeconomy Strategy provides the overarching policy framework. The Renewable Energy Directive III (RED III) defines sustainability criteria for bio-based feedstocks. The EU Taxonomy Regulation classifies bio-based manufacturing activities for sustainable finance eligibility. REACH registration applies to novel bio-based chemicals. The Novel Food Regulation governs precision-fermented food ingredients through EFSA. The Single-Use Plastics Directive and Packaging and Packaging Waste Regulation create demand for recycled and bio-based packaging materials.

Q: How do I calculate the carbon benefit of switching to biomanufactured inputs? A: Request cradle-to-gate lifecycle assessments (LCAs) conducted per ISO 14044 from suppliers. Compare against petrochemical equivalents using Ecoinvent or GaBi databases. Key variables include: feedstock carbon intensity (sugar vs. waste gas vs. CO2), electricity source for manufacturing, and co-product allocation methodology. Gas fermentation from waste carbon typically shows 70 to 90% lower carbon footprint than petrochemical routes. Sugar-based fermentation shows 30 to 60% reduction, depending on sugar source and energy inputs. Require third-party verified LCAs rather than self-reported figures.

Sources

• McKinsey Global Institute. (2025). The Bio Revolution: Innovations Transforming Economies, Societies, and Our Lives - 2025 Update. New York: McKinsey & Company.
• European Commission. (2024). EU Bioeconomy Strategy Progress Report. Brussels: Directorate-General for Research and Innovation.
• Grand View Research. (2025). Industrial Biotechnology Market Size, Share & Trends Analysis Report, 2025-2030. San Francisco, CA.
• Crater, J.S. & Lievense, J.C. (2024). Scale-up of industrial microbial processes: A meta-analysis of yield retention across scales. Metabolic Engineering, 81, 45-58.
• Carbios. (2025). Annual Report 2024: First Industrial Enzymatic Recycling Plant Operations. Clermont-Ferrand, France.
• LanzaTech. (2025). CarbonSmart Platform: Commercial Gas Fermentation Performance Data. Skokie, IL.
• European Industrial Biotechnology Association. (2025). Bio-based Chemicals Market Report: European Outlook 2025-2035. Brussels: EuropaBio.